scholarly journals Prevalence of Chronic Fatigue Syndrome (CFS) in Korea and Japan: A Meta-Analysis

2021 ◽  
Vol 10 (15) ◽  
pp. 3204
Author(s):  
Eun-Jin Lim ◽  
Chang-Gue Son

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a long-term disabling illness accompanied by fatigue unsolved by rest. However, ME/CFS is a poorly understood illness that lacks a universally accepted pathophysiology and treatment. A lack of CFS-related studies have been conducted in Asian countries. This study aimed to estimate and compare the prevalence of ME/CFS in Korea and Japan and conducted a meta-analysis. Methods: We searched PubMed, EMBASE, Cochrane, and KMBASE for population-based prevalence studies of the two countries and synthesized the data according to the Fukuda case definition. Results: Of the eight studies (five in Korea, three in Japan) included, the total prevalence rate of Korean studies was 0.77% (95% CI 0.34–1.76), and 0.76% (95% CI 0.46–1.25) for the Japanese studies. The prevalence rate in females was approximately two-fold higher than males in Korean studies (1.31% female vs. 0.60% male), while the gender difference was less obvious in Japanese studies (0.76% female vs. 0.65% male). Conclusions: Further epidemiology studies on the female ME/CFS prevalence rate between countries may be required.

2004 ◽  
Vol 10 (2) ◽  
pp. 278-285 ◽  
Author(s):  
KIM BUSICHIO ◽  
LANA A. TIERSKY ◽  
JOHN DELUCA ◽  
BENJAMIN H. NATELSON

The degree of neuropsychological dysfunction across multiple domains was examined in individuals suffering from chronic fatigue syndrome (CFS). In this descriptive study, a similar series of neuropsychological tests was administered to a group of CFS patients and healthy participants. More specifically, CFS patients (n = 141) who met the 1994 Case Definition criteria were compared to 76 healthy control participants on tests of memory, attention (concentration), speed of information processing, motor speed, and executive functioning. On the 18 measures administered, CFS patients scored 1 standard deviation below the healthy mean on nine measures and scored 2 standard deviations below the healthy mean on four of the measures. Moreover, results indicated that CFS patients were more likely than healthy controls to fail (1.6 SD below the healthy mean) at least one test in each of the following domains: attention, speed of information processing, and motor speed, but not on measures of memory and executive functioning. Finally, CFS patients demonstrated a greater total number of tests failed across domains. (JINS, 2004, 10, 278–285.)


2015 ◽  
Vol 3 (1) ◽  
pp. 82-93 ◽  
Author(s):  
Leonard A. Jason ◽  
Bobby Kot ◽  
Madison Sunnquist ◽  
Abigail Brown ◽  
Meredyth Evans ◽  
...  

2006 ◽  
Vol 13 (2-3) ◽  
pp. 1-44 ◽  
Author(s):  
Leonard A. Jason ◽  
Karen Jordan ◽  
Teruhisa Miike ◽  
David S. Bell ◽  
Charles Lapp ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Jianyu You ◽  
Jing Ye ◽  
Haiyan Li ◽  
Wenguo Ye ◽  
Ensi Hong

Objective. This review aimed at systematically evaluating the efficacy and safety of moxibustion for chronic fatigue syndrome (CFS). Methods. Relevant trials were searched in seven digital databases up to January 2021. After literature screening, data extraction, and literature quality evaluation, the included studies were meta-analyzed using RevMan 5.4 software. The evidence level was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Results. Fifteen studies involving 1030 CFS participants were included. Meta-analyses showed a favorable effect of moxibustion on the total effective rate compared with acupuncture (OR = 4.58, 95%CI = [2.85, 7.35], P < 0.00001 ) and drugs (OR = 6.36, 95%CI = [3.48, 11.59], P < 0.00001 ). Moxibustion also appeared to significantly reduce fatigue severity measured by fatigue scale-14 (FS-14) (WMD = −2.20, 95% CI = [−3.16, −1.24], P < 0.00001 ) and fatigue assessment instrument (FAI) (WMD = −16.36, 95% CI = [−26.58, −6.14], P = 0.002 ) compared with the control group. In addition, among the 15 included studies, only two studies reported adverse events related to moxibustion, and the symptoms were relatively mild. The quality of evidence based on the 15 included trials was assessed as moderate to very low. Conclusions. Based on limited evidence, moxibustion might be an effective and safe complementary therapy for CFS, which can be recommended to manage CFS. Because of the limited level of evidence in this review, further high-quality trials are still needed to confirm these findings.


Sign in / Sign up

Export Citation Format

Share Document